Pfizer: Hyperimmune Response in Children 5 to 11 Years Old After COVID-19 Booster
- Engineered Soybeans with Pig Protein: A Promising Alternative or Pandora’s Dish?
- Severe Fever with Thrombocytopenia Syndrome (SFTS): A Tick-Borne Threat with High Mortality
- Why Isolating Bananas Extends Their Shelf Life?
- This common vitamin benefits the brain and prevents cognitive decline
- New report reveals Nestlé adding sugar to infant formula sold in poor countries
- Did Cloud Seeding Unleash a Deluge in Dubai?
Pfizer: Hyperimmune Response in Children 5 to 11 Years Old After COVID-19 Booster vaccine
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Pfizer: Hyperimmune Response in Children 5 to 11 Years Old After COVID-19 Booster vaccine.
U.S. drugmakers Pfizer and BioNTech released clinical trial data on Thursday (April 14) that showed that children between the ages of 5 and 11 had a 36-fold increase in antibodies against the mutant strain of Omicron after receiving a booster dose of the coronavirus vaccine. (Reuters file photo)
Pfizer and BioNTech released clinical trial data on Thursday (April 14) showing that children between the ages of 5 and 11 received a booster dose of the coronavirus vaccine, antibodies against the mutant strain of Omicron increased 36 times.
According to a joint statement, the two companies plan to submit the data to the U.S. Food and Drug Administration for emergency use authorization in the next few days. At the same time, there are also plans to submit applications for authorization to other regulators around the world.
The data “strengthen the potential ability of the third dose to maintain high protection against Covid-19 in this age group,” the statement said.
According to reports, in the clinical trial, 140 children between the ages of 5 and 11 received a booster dose of 10 micrograms half a year after the second dose of the coronavirus vaccine. One month after the booster dose, they had six times more antibodies against the original coronavirus strain than one month after the second dose.
The researchers also found that 30 children who received the booster had a 36-fold increase in neutralizing antibodies against the Omicron strain.
It also highlighted that people have responded well to the supplement and that no new safety concerns have been identified.
Pfizer: ‘Hyperimmune Response’ in Children 5 to 11 Years Old After COVID-19 Booster vaccine
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
